İbrahim TOPCU, Ahmet AKICI, Sinem Ezgi GÜLMEZ, Dilek DEMİRCAN, Hüseyin YILMAZ, Başak DÖNERTAŞ, Kemal BERKMAN

Use of drugs subject to controlled prescriptions: a retrospective analysis

Objective: Use of drugs that may lead to abuse or dependence are subject to controlled prescriptions (CPs) in many countries, and these are closely monitored by health authorities. According to national regulations in Turkey, CPs may be red coloured (RCPs) or green coloured (GCPs). The aim of this study was to evaluate the use of such drugs in Istanbul. Study Design: Retrospective case-control study. Material and Methods: During the study period (01/01-31/12 2009), 502874 CPs were reported. Among these, 4000 CPs each month were randomly selected and evaluated. Results: The majority of GCPs were issued to women (55.6%), while the majority of RCPs were issued to men (68.4%). GCPs were most frequently prescribed by physicians working in private hospitals (33.6%) while RCPs by physicians working in university hospitals (39.7%). GCPs were mostly pre- scribed by psychiatrists (37.6%) while for RCPs were child and adolescent psychiatrists (35.9%). Psycholeptics (ATC code N05) were the most prescribed controlled drugs (CDs) (43.8%). Methylphenidate (53.9%) was the mostly prescribed on RCPs and alprazolam (39.6%) was on GCPs. Conclusion: We demonstrate that utilization of CDs shows demographical and institutional differences. These data could be of help to improve surveil- lance of CDs as well as to train prescribers and patients.

PDF

___

1. United Nations. Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961. http://www.incb.org/pdf/e/conv/ convention_1961_en.pdf. Accessed:08.05.2012.
2. United Nations. Convention on Psychotropic Substances, 1971. http://www.incb.org/pdf/e/conv/convention_1971_en.pdf. Accessed:08.05.2012.
3. United Nations. Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. http://www.incb.org/ pdf/e/conv/1988_convention_en.pdf. Accessed:08.05.2012.
4. United Nations Office on Drugs and Crime (UNODC). Ensuring availability of controlled medications for the relief of pain and preventing diversion and abuse:Striking the right balance to achieve the optimal public health outcome. Vienna, 2011.
5. Republic of Turkey The Official Gazette. Circular letter regarding the prescriptions of substances and drugs subject to control. 29.05.1985, Number:5768. [T.C Resmi Gazete Kontrole Tabi Uyuşturucu Madde ve Müstahzarların Reçeteleri Hakkında Genelge. 29 Mayıs 1985, Sayı:5768].
6. Republic of Turkey The Official Gazette. Circular letter regarding the prescriptions of psychotropic medications. 02.01.1986, Number:09/2677. [T.C Resmi Gazete Psikotrop İlaç Reçeteleri Hakkında Genelge. 02.01.1986, 09/2677].
7. World Health Organization (WHO). Improving access and use of psychotropic medicines (Mental health policy and service guidance package), 2005.
8. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011. United Nations Publication, Sales No. E.11. XI.10.
9. Prueksaritanond S, Tubtimtes S, Pumkompol T, Sukying C. Psychotropic drug prescribing in the family medicine out-patient clinic, Ramathibodi Hospital. J Med Assoc Thai 2009;92:266-72.
10. Westbury JL, Jackson S, Peterson GM. Psycholeptic use in aged care homes in Tasmania, Australia. J Clin Pharm Ther 2010;35:189-93. [CrossRef]
11. Fortuna RJ, Robbins BW, Caiola E, Joynt M, Halterman JS. Prescribing of controlled medications to adolescents and young adults in the United States. Pediatrics 2010;126:1108-16. [CrossRef]
12. John U, Baumeister SE, Völzke H, Grabe HJ, Freyberger HJ, Alte D. Estimation of psycholeptic and psychoanaleptic medicine use in an adult general population sample using the Anatomical Therapeutic Chemical classification. Int J Methods Psychiatr Res 2008;17:220-31. [CrossRef]
13. Svab V, Subelj M, Vidmar G. Prescribing changes in anxiolytics and antidepressants in Slovenia. Psychiatr Danub 2011;23:178- 82.
14. McCabe SE, West BT, Teter CJ, Ross-Durow P, Young A, Boyd CJ. Characteristics associated with the diversion of controlled medications among adolescents. Drug Alcohol Depend 2011;118:452-8. [CrossRef]
15. Eggen AE. The use of controlled analgesics in a general population (15-59 years)-the influence of age, gender, morbidity, lifestyle and sociodemographic factors. Pharmacoepidemiol Drug Saf 1996;5:101-11. [CrossRef]
16. Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink PC. Prescriptions of opioids to children and adolescents;a study from a national prescription database in Norway. Paediatr Anaesth 2010;20:537-44. [CrossRef]
17. De Vries TPGM, Henning RH, Hogerzeil HV, Fresle DA. Guide to Good Prescribing. WHO/Action programme on essential drugs, Geneva, 1994.
18. Bollan W, Simon C. Controlled drugs:regulations and prescribing. InnovAiT 2008;1:163-71. [CrossRef]
19. National Institute for Health & Clinical Excellence (NICE). The NICE Guideline on diagnosis and management of ADHD in children, young people and adults. The British Psychological Society and The Royal College of Psychiatrists, London, 2009.
20. Subcommittee on Attention-deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD:Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2011;128:1-16. [CrossRef]
21. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. 3th edition, 2010.
22. Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders:a systematic review of the literature. Can J Psychiatry 2006;51:100-13.
23. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety disorders in older adults:a comprehensive review. Depress Anxiety 2010;27:190-211. [CrossRef]
24. National Institute of Mental Health. Anxiety disorders in children and adolescents fact sheet. http://www.nimh.nih. gov/health/publications/anxiety-disorders-in-children-and- adolescents/anxiety-disorders-in-children-and-adolescents.pdf. Accessed:08.05.2012.
25. Republic of Turkey Ministry of Development. Report of Health Education and Healthcare Human Resources in Turkey. Ankara, June 2010. ISBN:978-975-7912-37-8. [T.C Başbakanlık Devlet Planlama Teşkilatı Müsteşarlığı. Türkiyede Sağlık Eğitimi ve Sağlık İnsan Gücü Durum Raporu].
26. World Health Organization (WHO). Disease control priorities related to mental, neurological, developmental and substance abuse disorders. Switzerland, 2006.
27. World Health Organization (WHO). Gender and womens mental health, Gender disparities and mental health:The Facts. http:// www.who.int/mental_health/prevention/genderwomen/en/. Accessed:08.05.2012.
28. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States:results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23. [CrossRef]
29. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder:meta- analysis. Br J Psychiatry 2009;194:204-11. [CrossRef]
30. Noto AR, de A Carlini E, Mastroianni PC, Alves VC, Galduróz JCF, Kuroiwa W, et al. Analysis of prescription and dispensation of psychotropic medications in two cities in the State of São Paulo, Brazil. Rev Bras Psiquiatr 2002;24:68-73. [CrossRef]
31. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy and the United Kingdom. J Clin Psychiatry 2002;63:817-25. [CrossRef]
32. Prueksaritanond S, Tubtimtes S, Pumkompol T, Sukying C. Psychotropic drug prescribing in the family medicine out-patient clinic, Ramathibodi Hospital. J Med Assoc Thai 2009;92:266-72.
33. Markovic-Pekovic V, Stoisavljevic-Satara S, Skrbic R. Outpatient utilization of drugs acting on nervous system:a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Pharmacol 2010;66:177-86. [CrossRef]
34. Kanavos P, Üstel İ, Font JC. Healthcare/Pharmaceutical Spending and Pharmaceutical Reimbursement Policy in Turkey. New Hope in Health Foundation (SUVAK), 2005.
35. Lieberman JA. The use of antipsychotics in primary care. Primary Care Companion J Clin Psychiatry 2003;5:3-8.
36. Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998;51:273-83. [CrossRef]
37. United Nations. Report of the International Narcotics Control Board for 2010. New York, 2011. United Nations Publication Sales No. E.11.XI.1.
38. Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother 2011;25:6-18. [CrossRef]
39. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009;39:676-81. [CrossRef]
40. Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007 - pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-94. [CrossRef]